Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

NMO and the evolving spectrum of water channel autoimmunity Water channels are a newly recognized target for central nervous system (CNS), inflammatory autoimmune demyelinating diseases. Neuromyelitis optica (NMO; aka optic spinal multiple sclerosis) is a devastating disease that disproportionally affects non-Caucasians. It is characterized by recurrent episodes of optic neuritis and transverse myelitis, which may result in blindness and paraplegia. It is frequently misdiagnosed as multiple sclerosis (MS). NMO is the first MS-like disease for which a specific antigen has been identified – the astrocytic water channel aquaporin-4 (AQP4). This discovery represents a seismic shift from historic emphasis on the oligodendrocyte and myelin to the astrocyte. An autoantibody specific for AQP4 (NMO/AQP4-IgG) is a clinically validated serum biomarker that distinguishes relapsing NMO from MS. MS has no distinguishing biomarker and calls for different therapies. The traditional view-Devic's disease In 1894, Devic reported a case of combined optic neuritis and myelitis that was fatal and provided a review of 16 similar cases from the literature. The syndrome that Devic described was a monophasic illness characterized by both bilateral optic neuritis and transverse myelitis occurring at the same time. The lack of involvement of the brain was emphasized. Over the following 100 years, many investigators reported single cases or case series of patients with variations on this theme. It became increasingly recognized that patients may have (1) unilateral rather then bilateral optic neuritis, and (2) interval of weeks to years between attacks of optic neuritis and myelitis rather then simultaneous onset. Subsequently it was recognized that NMO was a relapsing disease in at least 80% of cases. Investigators put forward diagnostic criteria for NMO, all of which emphasized restriction of clinical symptoms and signs to the optic nerves and spinal cord and a normal brain MRI.– Longitudinally extensive T2 signal abnormalities spanning three or more vertebral segments were reported to be characteristic of NMO, a situation rarely found in MS where lesions (at least in adults) are generally asymmetric and short. Over this period of time, NMO or Devic's syndrome was considered by most to be a variant of MS.

Original languageEnglish (US)
Title of host publicationMultiple Sclerosis Therapeutics, Fourth Edition
PublisherCambridge University Press
Pages614-631
Number of pages18
Volume9780521766272
ISBN (Print)9781139023986, 9780521766272
DOIs
StatePublished - Dec 1 2011

Fingerprint

Neuromyelitis Optica
Optic Neuritis
Multiple Sclerosis
Aquaporin 4
Aquaporins
Therapeutics
Transverse Myelitis
Myelitis
CNS Demyelinating Autoimmune Diseases
Biomarkers
Research Personnel
Paraplegia
Oligodendroglia
Brain
Blindness
Optic Nerve
Myelin Sheath
Diagnostic Errors
Autoimmunity
Astrocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pittock, S. J. (2011). Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders. In Multiple Sclerosis Therapeutics, Fourth Edition (Vol. 9780521766272, pp. 614-631). Cambridge University Press. https://doi.org/10.1017/CBO9781139023986.056

Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders. / Pittock, Sean J.

Multiple Sclerosis Therapeutics, Fourth Edition. Vol. 9780521766272 Cambridge University Press, 2011. p. 614-631.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pittock, SJ 2011, Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders. in Multiple Sclerosis Therapeutics, Fourth Edition. vol. 9780521766272, Cambridge University Press, pp. 614-631. https://doi.org/10.1017/CBO9781139023986.056
Pittock SJ. Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders. In Multiple Sclerosis Therapeutics, Fourth Edition. Vol. 9780521766272. Cambridge University Press. 2011. p. 614-631 https://doi.org/10.1017/CBO9781139023986.056
Pittock, Sean J. / Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders. Multiple Sclerosis Therapeutics, Fourth Edition. Vol. 9780521766272 Cambridge University Press, 2011. pp. 614-631
@inbook{556dc1d811c049db8e391a25af91dcef,
title = "Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders",
abstract = "NMO and the evolving spectrum of water channel autoimmunity Water channels are a newly recognized target for central nervous system (CNS), inflammatory autoimmune demyelinating diseases. Neuromyelitis optica (NMO; aka optic spinal multiple sclerosis) is a devastating disease that disproportionally affects non-Caucasians. It is characterized by recurrent episodes of optic neuritis and transverse myelitis, which may result in blindness and paraplegia. It is frequently misdiagnosed as multiple sclerosis (MS). NMO is the first MS-like disease for which a specific antigen has been identified – the astrocytic water channel aquaporin-4 (AQP4). This discovery represents a seismic shift from historic emphasis on the oligodendrocyte and myelin to the astrocyte. An autoantibody specific for AQP4 (NMO/AQP4-IgG) is a clinically validated serum biomarker that distinguishes relapsing NMO from MS. MS has no distinguishing biomarker and calls for different therapies. The traditional view-Devic's disease In 1894, Devic reported a case of combined optic neuritis and myelitis that was fatal and provided a review of 16 similar cases from the literature. The syndrome that Devic described was a monophasic illness characterized by both bilateral optic neuritis and transverse myelitis occurring at the same time. The lack of involvement of the brain was emphasized. Over the following 100 years, many investigators reported single cases or case series of patients with variations on this theme. It became increasingly recognized that patients may have (1) unilateral rather then bilateral optic neuritis, and (2) interval of weeks to years between attacks of optic neuritis and myelitis rather then simultaneous onset. Subsequently it was recognized that NMO was a relapsing disease in at least 80{\%} of cases. Investigators put forward diagnostic criteria for NMO, all of which emphasized restriction of clinical symptoms and signs to the optic nerves and spinal cord and a normal brain MRI.– Longitudinally extensive T2 signal abnormalities spanning three or more vertebral segments were reported to be characteristic of NMO, a situation rarely found in MS where lesions (at least in adults) are generally asymmetric and short. Over this period of time, NMO or Devic's syndrome was considered by most to be a variant of MS.",
author = "Pittock, {Sean J}",
year = "2011",
month = "12",
day = "1",
doi = "10.1017/CBO9781139023986.056",
language = "English (US)",
isbn = "9781139023986",
volume = "9780521766272",
pages = "614--631",
booktitle = "Multiple Sclerosis Therapeutics, Fourth Edition",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders

AU - Pittock, Sean J

PY - 2011/12/1

Y1 - 2011/12/1

N2 - NMO and the evolving spectrum of water channel autoimmunity Water channels are a newly recognized target for central nervous system (CNS), inflammatory autoimmune demyelinating diseases. Neuromyelitis optica (NMO; aka optic spinal multiple sclerosis) is a devastating disease that disproportionally affects non-Caucasians. It is characterized by recurrent episodes of optic neuritis and transverse myelitis, which may result in blindness and paraplegia. It is frequently misdiagnosed as multiple sclerosis (MS). NMO is the first MS-like disease for which a specific antigen has been identified – the astrocytic water channel aquaporin-4 (AQP4). This discovery represents a seismic shift from historic emphasis on the oligodendrocyte and myelin to the astrocyte. An autoantibody specific for AQP4 (NMO/AQP4-IgG) is a clinically validated serum biomarker that distinguishes relapsing NMO from MS. MS has no distinguishing biomarker and calls for different therapies. The traditional view-Devic's disease In 1894, Devic reported a case of combined optic neuritis and myelitis that was fatal and provided a review of 16 similar cases from the literature. The syndrome that Devic described was a monophasic illness characterized by both bilateral optic neuritis and transverse myelitis occurring at the same time. The lack of involvement of the brain was emphasized. Over the following 100 years, many investigators reported single cases or case series of patients with variations on this theme. It became increasingly recognized that patients may have (1) unilateral rather then bilateral optic neuritis, and (2) interval of weeks to years between attacks of optic neuritis and myelitis rather then simultaneous onset. Subsequently it was recognized that NMO was a relapsing disease in at least 80% of cases. Investigators put forward diagnostic criteria for NMO, all of which emphasized restriction of clinical symptoms and signs to the optic nerves and spinal cord and a normal brain MRI.– Longitudinally extensive T2 signal abnormalities spanning three or more vertebral segments were reported to be characteristic of NMO, a situation rarely found in MS where lesions (at least in adults) are generally asymmetric and short. Over this period of time, NMO or Devic's syndrome was considered by most to be a variant of MS.

AB - NMO and the evolving spectrum of water channel autoimmunity Water channels are a newly recognized target for central nervous system (CNS), inflammatory autoimmune demyelinating diseases. Neuromyelitis optica (NMO; aka optic spinal multiple sclerosis) is a devastating disease that disproportionally affects non-Caucasians. It is characterized by recurrent episodes of optic neuritis and transverse myelitis, which may result in blindness and paraplegia. It is frequently misdiagnosed as multiple sclerosis (MS). NMO is the first MS-like disease for which a specific antigen has been identified – the astrocytic water channel aquaporin-4 (AQP4). This discovery represents a seismic shift from historic emphasis on the oligodendrocyte and myelin to the astrocyte. An autoantibody specific for AQP4 (NMO/AQP4-IgG) is a clinically validated serum biomarker that distinguishes relapsing NMO from MS. MS has no distinguishing biomarker and calls for different therapies. The traditional view-Devic's disease In 1894, Devic reported a case of combined optic neuritis and myelitis that was fatal and provided a review of 16 similar cases from the literature. The syndrome that Devic described was a monophasic illness characterized by both bilateral optic neuritis and transverse myelitis occurring at the same time. The lack of involvement of the brain was emphasized. Over the following 100 years, many investigators reported single cases or case series of patients with variations on this theme. It became increasingly recognized that patients may have (1) unilateral rather then bilateral optic neuritis, and (2) interval of weeks to years between attacks of optic neuritis and myelitis rather then simultaneous onset. Subsequently it was recognized that NMO was a relapsing disease in at least 80% of cases. Investigators put forward diagnostic criteria for NMO, all of which emphasized restriction of clinical symptoms and signs to the optic nerves and spinal cord and a normal brain MRI.– Longitudinally extensive T2 signal abnormalities spanning three or more vertebral segments were reported to be characteristic of NMO, a situation rarely found in MS where lesions (at least in adults) are generally asymmetric and short. Over this period of time, NMO or Devic's syndrome was considered by most to be a variant of MS.

UR - http://www.scopus.com/inward/record.url?scp=84927080361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927080361&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139023986.056

DO - 10.1017/CBO9781139023986.056

M3 - Chapter

AN - SCOPUS:84927080361

SN - 9781139023986

SN - 9780521766272

VL - 9780521766272

SP - 614

EP - 631

BT - Multiple Sclerosis Therapeutics, Fourth Edition

PB - Cambridge University Press

ER -